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Abstract
Background: Journal abstracts including those reporting systematic reviews (SR) should contain sufficiently clear
and accurate information for adequate comprehension and interpretation. The aim was to compare the quality of
reporting of abstracts of SRs including meta-analysis published in high-impact general medicine journals before and
after publication of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for
abstracts (PRISMA-A) released in April 2013.
Methods: SRs including meta-analysis of randomized controlled trials published in 2012, 2014, and 2015 in top-tier
general medicine journals were searched in PubMed. Data was selected and extracted by two reviewers based on
the PRISMA-A guidelines which recommend to include 12 items. The primary outcome was the adjusted mean
number of items reported; the secondary outcome was the reporting of each item and factors associated with a
better reporting. Adjustment was made for abstract word count and format, number of authors, PRISMA endorsement,
and publication on behalf of a group.
Results: We included 84 abstracts from 2012, 59 from 2014, and 61 from 2015. The mean number of items reported in
2015 (7.5; standard deviation [SD] 1.6) and in 2014 (6.8; SD 1.6) differed and did not differ from that reported in
2012 (7.2; SD 1.7), respectively; adjusted mean difference: 0.9 (95 % CI 0.4; 1.3) and −0.1 (95 % CI −0.6; 0.4). From
2012 to 2014, the quality of reporting was in regression for “strengths and limitations of evidence” and “funding”;
contrariwise, it remained unchanged for the others items. Between 2012 and 2015, the quality of reporting rose
up for “description of the effect”, “synthesis of results”, “interpretation”, and “registration”; but decreased for “strengths
and limitations of evidence”; it remained unchanged for the other items. The overall better reporting was associated
with abstracts structured in the 8-headings format in 2014 and abstracts with a word count <300 in 2014 and 2015.
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Conclusions: Not surprisingly, the quality of reporting did not improve in 2014 and suboptimally improved in 2015.
There is still room for improvement to meet the standards of PRISMA-A guidelines. Stricter adherence to these
guidelines by authors, reviewers, and journal editors is highly warranted and will surely contribute to a better reporting.
Keywords: Abstract, PRISMA, Systematic review, Randomized controlled trial, Meta-analysis, General medicine journal
Background
Systematic reviews and meta-analyses of randomized
controlled trials (RCTs) are fundamental tools which can
be used to generate reliable summaries of health care in-
formation directed to clinicians, decision makers, and
patients as well [1]. RCTs by their design generally pro-
vide the best quality of evidence required for health care
decisions about interventions compared to observational
studies [2, 3]. As such, they should be reported according
to the highest possible pre-defined standards, as well as
their systematic reviews and meta-analyses. Indeed, system-
atic reviews of RCTs provide information on clinical bene-
fits and harms of interventions, inform the development of
clinical recommendations, and help to identify future re-
search needs. Besides, they are the reference standard for
synthesizing evidence in healthcare about interventions
because of their methodological rigor [4]. Clinicians read
them to keep up to date with their field [5, 6]. As with any
other research, the value of a systematic review depends on
what was done, what was found, and the clarity of its
reporting. Like other publications, low quality of reporting
of systematic reviews can limit readers’ ability to assess the
strengths and weaknesses of these reviews.
With an overwhelming day-to-day workload, the avail-
ability of large volumes of scientific publications, limited
access to many full-text articles, healthcare professionals
often make recourse to information contained in abstracts
to guide or sustain their decisions [7, 8]. Within queries to
PubMed, most readers look only at titles; only half of
searches result in any click on content [9]. What makes
matters worse, the average number of titles clicked on to
obtain the abstract or full text, even after retrieving several
searches in a row, is less than five. Of those clicks, ab-
stracts will be represented about 2.5 times more often
than full texts [9].
Abstracts can be useful for: screening by study type, facili-
tating quick assessment of validity, enabling efficient per-
usal of electronic search results, clarifying to which patients
and settings the results apply, providing readers and peer
reviewers with explicit summaries of results, facilitating the
pre-publication peer review process, and increasing preci-
sion of computerized searches [10–13]. Consequently, jour-
nal and conference abstracts must contain sufficiently clear
and accurate information that will permit adequate com-
prehension and interpretation of systematic reviews and
meta-analyses findings [14].
After observing that the quality of abstracts of systematic
reviews is still poor [15], the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) for
Abstracts Group developed an extension to the PRISMA
Statement in order to provide guidance on how to write
and present abstracts for systematic reviews and meta-
analyses [14]. These guidelines were published in April 9
2013. To the best of our knowledge, there is no published
study that has scrutinized the impact of release of PRISMA
for abstracts (PRISMA-A) yet, comparing the quality of
abstracts of papers published before (2012) and after (2014
and 2015) this release. Consequently, in an effort to pro-
mote quality reports of abstracts in systematic reviews and
meta-analyses of RCTs, we firstly compared the quality of
reporting abstracts in high-impact biomedical journals,
before and after publication of PRISMA guidelines for
abstracts. The secondary objectives included comparing
the quality of reporting of each item of PRISMA-A guide-
lines before and after the publication of PRISMA-A. We
also aimed to investigate factors associated with better
adherence to PRISMA-A guidelines.
Methods
Design
We identified abstracts of systematic reviews published
in 2012, 2014, and 2015 in high-impact general medicine
journals. We assessed the reporting of these abstracts
according to PRISMA-A recommendations [14]. We
compared reporting from 2012 (before PRISMA-A) with
reporting in 2014 and 2015 (after PRISMA-A). The
present review was not registered. The PRISMA guide-
lines served as the template for reporting the present re-
view [16]. The PRISMA checklist can be found in the
Additional file 1.
Data sources
Based on impact factor published in 2015 by Thomson
Reuters [17], the top nine high-impact general medical
journals were selected for this study, namely: New
England Journal of Medicine (NEJM), The Lancet,
Journal of American Medical Association (JAMA),
Annals of Internal Medicine, British Medical Journal
(BMJ), Archives of Internal Medicine, PLOS Medicine,
JAMA Internal Medicine, BMC Medicine, and Mayo
Clinic Proceedings. In the PRISMA website, NEJM,
Annals of Internal Medicine, Archives of Internal Medicine,
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and Mayo Clinic Proceedings are not cited as endorsers of
PRISMA guidelines by contrast to the other journals which
are PRISMA endorsers [18]. Journals were not excluded on
the basis of their lack of endorsement of the PRISMA state-
ment. We conducted a PubMed search of all systematic re-
views and meta-analyses published in years 2012, 2014, and
2015. Our search strategy included “meta-analysis” as publi-
cation type, journal names, and limits were set for the spe-
cific time periods of interest (2012/01/01 to 2012/12/31,
2014/01/01 to 2014/12/31, and 2015/01/01 to 2015/12/31).
The search strategy is presented in the Additional file 2.
Studies selection and data extraction
Two reviewers (JJRB and LNU) independently selected
abstracts of systematic reviews of RCTs including meta-
analyses. A “yes” or “no” answer was assigned to each
item indicating whether the authors had reported it or
not. Data extraction was independently performed by
two reviewers (JJRB and LNU) in compliance with rec-
ommendations of the evaluation of PRISMA-A guide-
lines [14]. This was done for the 12 items recommended
by the PRISMA-A guidelines. Agreement was measured
using the Kappa statistic [19]. Disagreements were re-
solved by consensus after discussion between authors.
In addition to the PRISMA-A items, we collected the
journal name, number of authors, type of abstract format
(Introduction, Methods, Results, and Discussion [IMRAD];
8-headings [objective, design, setting, participants, interven-
tion, main outcome measured, results, and conclusions]),
PRISMA endorser journal (yes or no), and actual observed
abstract word count (<300 versus ≥300).
Outcomes measured
The primary outcome was the number of items reported
among the 12 recommended items of the PRISMA-A
guidelines; the secondary one was the proportion of ab-
stracts reporting each of these 12 recommended items.
Statistical analysis
Data were entered and analyzed using the Statistical
Package for Social Science (SPSS) version 21.0 for Windows
(IBM Corp. Released 2012. IBM SPSS Statistics for
Windows, Version 21.0. Armonk, NY: IBM Corp.). Cat-
egorical variables were expressed as numbers (N) with
percentages (%). Continuous variables were expressed as
means with standard deviation (SD).
We expressed the number of items for each year as mean
(SD) and estimated the unadjusted and adjusted differences
using the independent two-sample Student t test and
generalized estimation equations (GEE), respectively [20].
The mean differences and adjusted means were reported
with their 95 % confidence intervals (95 % CI) and p values.
For continuous variables (number of items reported, for ex-
ample), we assumed a linear distribution. We compared
compliance with the 12 items of the PRISMA-A for years
2012 versus 2014 and 2015 using individual chi-squared
test or Fischer’s exact test where necessary. Unadjusted ana-
lysis was followed by an adjusted analysis using GEE. For
binary outcomes, we assumed a binomial distribution and
an unstructured correlation matrix. We reported measures
of association with odds ratios (OR) for univariable analyses
and adjusted odds ratios (aOR) for multivariable analyses
together with their 95 % confidence intervals (CI) and p
values. Factors associated with overall better reporting were
investigated using GEE and assuming Poisson distribution
for number of items reported. The magnitude of associ-
ation between better reporting and investigated factors was
measured with adjusted incidence rate ratio (aIRR) along-
side its 95 % CI. Additionally, we conducted sensitive
analyses to determine factors associated with a better
quality of reporting of the “Methods” and “Results” sec-
tions of abstracts for years 2014 and 2015.
For GEE, adjustments were made for actual observed
abstract word count (<300 versus ≥300), PRISMA endorser
journal (yes versus no), abstract format (IMRAD versus 8-
headings), publication on behalf of a group (yes versus no),
number of authors (≤6 versus >6), with journal as a group-
ing factor to adjust for potential clustering or similarity in
articles published in the same journal. Evidence against the
null hypothesis was considered for a two-tailed p value
of <0.05. The 300-word cut-off was chosen as it has
been shown, like for other abstract reporting guidelines
such as the Consolidated Standards of Reporting Trials
(CONSORT) extension for abstracts, that a word count
around 300 is sufficient to fill all items [20]. The adjustment
was done for abstract format because there are previous
studies reporting relationship between abstract format and
quality reporting [21, 22]. The adjustment was also done
for number of authors and publication on behalf a group
because it was reported an association between higher
quality of work and increased number of collaborators
[23, 24], though some other studies did not end up with
the same finding [25, 26].
Results
General characteristics of abstracts selected
Our search yielded 505 articles of which 183 were
published in 2012, 192 in 2014, and 130 in 2015. Three
hundred and one abstracts did not meet our inclusion
criteria, hence were excluded because most of them not
included RCTs in the meta-analysis (n = 280). On the
whole, we included 204 abstracts: 84 from 2012, 59 from
2014, and 61 from 2015 as shown in the flow diagram
(Fig. 1). Agreement between reviewers on all PRISMA-A
items was high (Kappa = 0.79, p < 0.001). Additional file 3
lists all abstracts included in this review.
As concerns the journals in which the abstracts were
published, 67 (32.8 %) were published in BMJ (Table 1).
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- Annals of Internal Medicine 12 (14.3) 13 (22.0) 11 (18.0) 36 (17.6)
- BMC Medicine 4 (4.8) 8 (13.6) 10 (16.4) 22 (10.8)
- BMJ 31 (36.9) 18 (30.5) 18 (29.5) 67 (32.8)
- JAMA 6 (7.1) 6 (10.2) 4 (6.6) 16 (7.8)
- JAMA Internal Medicine/Archives of Internal Medicine 13 (15.5) 11 (18.6) 4 (6.6) 28 (13.7)
- Mayo Clinic Proceedings 1 (1.2) 3 (5.1) 0 4 (2.0)
- NEJM 1 (1.2) 0 0 1 (0.5)
- PLOS Medicine 6 (7.1) 0 0 6 (2.9)
- The Lancet 10 (11.9) 0 14 (23.0) 24 (11.8)
Mean number of authors 8.2 (5.8) 8.4 (5.4) 9.1 (4.9) 8.5 (5.4)
Abstract format
- IMRAD 35 (41.7) 12 (20.3) 25 (41.0) 72 (35.3)
- 8-headings 49 (58.3) 47 (79.7) 36 (59.0) 132 (64.7)
PRISMA endorser journals
- Yes 57 (67.9) 43 (72.9) 50 (82.0) 150 (73.5)
- No 27 (32.1) 16 (27.1) 11 (18.0) 54 (26.5)
Publication on behalf of a group
- Yes 8 (9.5) 4 (6.8) 7 (11.5) 19 (9.3)
- No 76 (90.5) 55 (93.2) 54 (88.5) 185 (90.7)
Actual observed abstract word count
- <300 14 (16.7) 16 (27.1) 11 (18.0) 41 (20.1)
- ≥300 70 (83.3) 43 (72.9) 50 (82.0) 163 (79.9)
Data are n (%) or mean (standard deviation)
Fig. 1 Flow chart of studies considered for inclusion
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The 8-headings format was used in 132 (64.7 %) abstracts.
Among all the journals, 163 (79.9) were published with an
actual observed abstract word count ≥300, 19 (9.3 %) ab-
stracts reported publications on behalf of a group in
authorship, and 150 abstracts (73.5 %) were from journals
which endorsed PRISMA. Four of the 10 journals were
PRISMA endorsers. The mean number of authors per art-
icle was 8.5 (SD 5.4) (Table 1).
Comparison of quality of abstract reporting between
2014 and 2012 and between 2015 and 2012
The mean number of items reported in 2014 (mean = 6.8;
SD = 1.6) did not statistically differ from that reported in
2012 (mean = 6.7; SD = 1.6), mean difference (MD): 0.1;
95 % CI −0.4; 0.7; p = 0.694. There was no statistically sig-
nificant difference after adjusting for covariates among
which actual observed abstract word count, PRISMA en-
dorsement, abstract format, publication on behalf of a
group, and number of authors (MD −0.1, 95 % CI −0.6;
0.4; p = 1.0). The mean number of items reported in 2015
(mean = 7.5; SD = 1.6) differed significantly from that re-
ported in 2012: mean difference (MD): 0.8; 95 % CI 0.2;
1.3; p = 0.007. This difference remained statistically signifi-
cant after adjustment for covariates (MD 0.9, 95 % CI 0.4;
1.3; p = 0.002) (Table 2). An exploratory comparison
between abstracts released in 2015 and those released
in 2014 with regard to the overall quality of reporting
showed a statistically significant difference (MD 0.63,
95 % CI 0.05; 1.21; p = 0.034).
Seven items were reported in more than 50 % of the
abstracts: title, objectives, eligibility criteria, included studies,
synthesis of results, description of effect, and interpretation.
Four items were reported in less than 50 % of the ab-
stracts: information sources, strengths and limitations
of evidence, funding, and registration. Reporting of risk of
bias varied, around 50 % throughout years (49.2–67.8 %)
(Table 3).
In univariable analysis, there was a statistically significant
improvement in abstract reporting in 2014 compared to
2012 only for “risk of bias” (crude OR [cOR] = 2.0; 95 % CI
1.003; 4.0). After adjustment, “risk of bias” became insignifi-
cant while reporting of “strengths and limitations of
evidence” (adjusted OR [aOR] = 0.23; 95 % CI 0.07–0.71)
and “Funding” (aOR = 0.25; 95 % CI 0.07–0.81) became
Table 2 Comparison of mean of PRISMA for abstracts items reported in abstracts of meta-analyses of RCT
Variables N Univariable analysisa Multivariable analysisb
Means (standard deviation) Mean difference
(95 % CI)






- 2012 (ref) 84 6.7 (1.6) 7.0 (6.5; 7.5) <0.001*
- 2014 59 6.8 (1.6) 0.1 (−0.4; 0.7) 0.694 6.9 (6.4; 7.4) −0.1 (−0.6; 0.4) 0.711**
- 2015 61 7.5 (1.6) 0.8 (0.2; 1.3) 0.007 7.8 (7.4; 8.3) 0.9 (0.4; 1.3) 0.001***
Abstract word count
- <300 (ref) 30 8.3 (2.0) 6.9 (6.3; 7.4)
- ≥300 113 6.7 (1.4) −0.3 (−1.3; −1.0) <0.001 7.6 (6.8; 8.4) 0.7 (−0.4; 1.8) 0.184
PRISMA endorsement
- Non endorser journals (ref) 43 7.9 (1.9) 7.7 (7.1; 8.2)
- Endorser journals 100 6.6 (1.4) −1.3 (−1.9; −0.7) <0.001 6.8 (6.2; 7.4) −0.8 (−1.7; 0.04) 0.063
Abstract format
- IMRAD (ref) 47 6.4 (1.6) 6.9 (6.3; 7.4)
- 8-headings 96 7.3 (1.6) 0.8 (0.4; 1.3) <0.001 7.6 (7.2; 8.0) 0.7 (0.2; 1.2) 0.008
Publication on behalf of a group
- No (ref) 131 7.0 (1.7) 7.3 (7.0; 7.7)
- Yes 12 6.7 (1.4) −0.3 (−1.1; 0.4) 0.394 7.1 (6.5; 7.8) −0.2 (−0.8; 0.5) 0.557
Number of authors
- ≤6 (ref) 64 6.9 (1.6) 0.1 (−0.4; 0.6) 0.659 7.2 (6.7; 7.6)
- >6 79 7.0 (1.7) 7.3 (6.9; 7.7) 0.2 (−0.3; 0.6) 0.464
Ref reference for mean difference calculation, PRISMA preferred reporting items for systematic review and meta-analysis, IMRAD introduction, methods, results,
and discussion
aStudent’s t test, *Global p value
bGeneralized estimation equations with journals as grouping variable. Goodness of Fit: value of the Corrected Quasi-likelihood under Independence Model
Criterion = 1827.12 and the value of the Quasi-likelihood under Independence Model Criterion = 1829.28
After Bonferroni correction for multiple comparisons, values are **1.0 and *** 0.002
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statistically associated with a lower quality in 2014 com-
pared to 2012 (Table 4).
In univariable analysis, there was a statistically signifi-
cant improvement in abstract reporting in 2015 compared
to 2012 for “synthesis of results” (cOR not estimable, p <
0.001), for “interpretation”
(cOR not estimable, p < 0.001), and for “registration”
(cOR = 12.2; 95 % CI 2.7–56.1). The quality of abstract
decreased from 2012 to 2015 concerning “strength and lim-
itations of evidence” (cOR = 0.38; 95 % CI 0.18–0.82). After
adjustment, “synthesis and results” (aOR not estimable, p <
0.001), “description of effect” (aOR = 2.7; 95 % CI 1.2–6.1),
“interpretation” (aOR not estimable, p < 0.001), and “regis-
tration” (aOR = 10.8; 95 % CI 2.3–49.6) were statistically
associated with a better quality of reporting in 2015 com-
pared to 2012. “Strengths and limitations of evidence” was







Title Identify the report as a meta-analysis 60 (98.4) 58 (98.3) 78 (92.9)
Objectives The research question including components such as participants,
interventions, comparators, and outcomes
52 (85.2) 45 (76.3) 68 (81.0)
Eligibility criteria Study and report characteristics used as criteria for inclusion 53 (86.9) 51 (86.4) 76 (90.5)
Information sources Key databases searched and search dates 7 (11.5) 15 (25.4) 11 (13.3)
Risk of bias Methods of assessing risk of bias 30 (49.2) 40 (67.8) 43 (51.2)
Included studies Number and type of included studies and participants and relevant
characteristics of studies
36 (59.0) 35 (59.3) 54 (64.3)
Synthesis of results Results for main outcomes (benefits and harms), including summary
measures and confidence intervals
61 (100) 42 (71.2) 57 (67.9)
Description of the effect Direction of the effect and size of the effect in terms meaningful to
clinicians and patients
46 (75.4) 34 (57.6) 51 (60.7)
Strengths and Limitations
of evidence
Brief summary of strengths and limitations of evidence 12 (19.7) 18 (30.5) 33 (39.3)
Interpretation General interpretation of the results and important implications 61 (100) 51 (86.4) 69 (82.1)
Funding Primary source of funding for the review 24 (39.3) 12 (20.3) 24 (28.6)
Registration Registration number and registry name 14 (23.0) 3 (5.1) 2 (2.4)
Table 4 Comparison of reporting quality of items of the PRISMA for abstracts of meta-analyses of RCT
Items Univariable analysisa Multivariable analysisb
2014 versus 2012 2015 versus 2012 2014 versus 2012 2015 versus 2012
Crude odds ratio
(95 % CI)
p Crude odds ratio
(95 % CI)
p Adjusted odds ratio
(95 % CI)
p Adjusted odds ratio
(95 % CI)
p
Title 4.5 (0.52; 38.1) 0.240 4.6 (0.54; 39.4) 0.239 4.4 (0.55; 35.1) 0.163 4.5 (0.46; 43.7) 0.199
Objectives 0.76 (0.34; 1.7) 0.499 1.4 (0.56; 3.3) 0.499 0.78 (0.33; 1.8) 0.564 1.6 (0.66; 4.1) 0.286
Eligibility criteria 0.67 (0.24; 1.9) 0.451 0.70 (0.25; 2.0) 0.496 0.58 (0.17; 2.0) 0.390 0.75 (0.25; 2.3) 0.617
Information sources 2.3 (0.95; 5.4) 0.060 0.86 (0.31; 2.4) 0.770 2.0 (0.70; 5.5) 0.197 0.82 (0.26; 2.6) 0.740
Risk of bias 2.0 (1.003; 4.0) 0.048 0.92 (0.48; 1.8) 0.811 1.2 (0.55; 2.7) 0.625 0.79 (0.36; 1.7) 0.550
Included studies 0.81 (0.41; 1.6) 0.547 0.80 (0.41; 1.6) 0.519 1.1 (0.52; 2.2) 0.834 0.98 (0.50; 2.7) 0.956
Synthesis of results 1.2 (0.57; 2.4) 0.671 Not estimable <0.001 1.1 (0.52; 2.5) 0.738 Not estimable
Description of the effect 0.88 (0.45; 1.7) 0.711 2.0 (0.96; 4.1) 0.063 0.93 (0.45; 1.9) 0.849 2.7 (1.2; 6.1) 0.014
Strengths and Limitations
of evidence
0.68 (0.34; 1.4) 0.281 0.38 (0.18; 0.82) 0.012 0.23 (0.07; 0.71) 0.011 0.13 (0.03; 0.66) 0.013
Interpretation 1.4 (0.07; 2.8) 0.474 Not estimable <0.001 1.9 (0.58; 5.9) 0.297 Not estimable
Funding 0.64 (0.29; 1.4) 0.264 1.6 (0.81; 3.3) 0.174 0.25 (0.07; 0.81) 0.021 1.5 (0.56; 4.0) 0.425
Registration 2.2 (0.36; 13.6) 0.404 12.2 (2.7; 56.1) <0.001 1.9 (0.30; 12.4) 0.485 10.8 (2.3; 49.6) 0.002
CI confidence interval
aChi-squared test
bGeneralized estimation equations with journal as grouping variable: adjustment has been made for abstract word count (<300 versus ≥300), PRISMA endorser
journal (yes versus no), abstract format (IMRAD versus 8-headings), publication on behalf a group (yes versus no), number of authors (≤6 versus >6)
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statistically associated with lower reporting quality in 2015
compared to 2012 (Table 4).
In 2014, factors statistically associated with overall
better reporting were structuring abstracts in the 8-headings
format compared to the IMRAD format (aIRR 1.26; 95 % CI
1.02–1.56) and abstract word count <300 (aIRR 1.20; 95 %
CI 1.09–1.35). The sole factor statistically associated with a
better reporting of the “Methods” section was abstract word
count <300 (aIRR 1.43; 95 % CI 1.16–1.72). None of the
researched factors was statistically associated with a better
quality of reporting of the “Results” section (Table 5).
In 2015, the sole factor statistically associated with an
overall better reporting was abstract word count <300
(aIRR 1.20; 95 % CI 1.09–1.35). Factors statistically associ-
ated with a better reporting of the “Methods” section was
abstract word count <300 (aIRR 1.43; 95 % CI 1.16–1.72),
structuring abstract in the 8-headings format compared to
the IMRAD format (aIRR 1.33; 95 % CI 1.08–1.65), and
not publishing on behalf of a group (aIRR 1.37; 95 % CI
1.04–1.82). No factor was statistically associated with a
better reporting of the “Results” section (Table 6).
Discussion
This study aimed to assess, according to the PRISMA-A
checklist, differences in the quality of reporting of ab-
stracts of systematic reviews and meta-analyses of RCTs
published in top-tier general medicine journals before
(in 2012) and after (in 2014 and 2015) publication of the
PRISMA extension for abstracts [14]. Our findings dem-
onstrate that the overall reporting quality of PRISMA
abstracts has not improved in the 2014 era as compared
to the pre-PRISMA-A era; however, there is a small im-
provement in 2015. There was no improvement of each of
the 12 items in 2014; in fact, two items regressed. There
was one regression and four improvements in 2015. The
sole factor associated with better reporting was presenting
abstracts following the 8-headings format.
These results are consistent with previous studies that re-
ported inconsistencies and patterns of suboptimal reporting
quality of abstracts across journals and fields of medicine
over time [21, 27–35]. As demonstrated by Hopewell and
colleagues, there are serious deficiencies in the reporting of
abstracts of systematic reviews which make it difficult for
readers to reliably assess study findings [36], although it has
been bolstered that the endorsement of PRISMA guidelines
increases adherence to recommendations [37].
Reporting of abstracts with the 8-headings format was
associated with an overall and “Results” section better
adherence to PRISMA-A guidelines in 2014. Actually,
the use of structured abstracts is warranted to improve
their quality of reporting [21, 22]. Surprisingly, abstract
word count <300 was associated with better reporting
overall, and better “Methods” section and “Results” sec-
tion reporting in 2014 and 2015. This indicates that a
word count of 300 is not too short to provide useful,
complete, and comprehensive information. In addition, it
has been demonstrated for the CONSORT guidelines that
checklist items can be easily incorporated within a word
count limit of 250 to 300 words [20]. We found that en-
dorsement of PRISMA was not statistically associated with
an improvement in the quality of abstracts. Therefore, edi-
tors, reviewers and authors should ensure that not only
the guidelines for the reporting of full texts are respected,
but also those for abstracts, as Hopewell and colleagues
have figured out huge discrepancies in the quality of
reporting between abstracts and full texts [36].
Table 5 Factors associated with a better reporting of items of PRISMA for abstracts published in 2014
Overall reporting quality Methods reporting quality Results reporting quality
Adjusted incidence rate ratios
(95 % confidence interval)a
p Adjusted incidence rate ratios
(95 % confidence interval)a
p Adjusted incidence rate ratios
(95 % confidence interval)a
p
Abstract word count
<300 (ref) 1 1
≥300 0.83 (0.74; 0.92) <0.001 0.70 (0.58; 0.86) <0.001 1.02 (0.78; 1.33) 0.878
Abstract format
IMRAD (ref) 1
8-headings 1.26 (1.02; 1.56) 0.036 1.40 (0.94; 2.10) 0.099 1.41 (0.91; 2.20) 0.126
Publication on behalf of a group
No (ref)
Yes 1.01 (0.88; 1.15) 0.911 0.85 (0.52; 1.38) 0.497 0.99 (0.62; 1.58) 0.965
Number of authors
≤6 (ref) 1
>6 1.02 (0.91; 1.14) 0.761 0.89 (0.73; 1.08) 0.242 1.05 (0.78; 1.41) 0.743
Ref reference for mean difference calculation, PRISMA preferred reporting items for systematic review and meta-analysis, IMRAD introduction, methods, results,
and discussion
aGeneralized estimation equations with journal as grouping variable. PRISMA endorser variable was excluded from model because it was redundant
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Our study presents some flaws. First, our study was based
on a limited number of published studies. Nonetheless, it
included all meta-analyses of RCT abstracts from high-
impact medical journals found in PubMed. Second, our
study may not be a representative sample of all medical
journals because we selected only general medicine journals
with high-impact factors. There is need for further studies
to investigate all types of systematic reviews and screen ran-
domly selected abstracts, not only from top-tier journals.
However, as our findings show that the quality of reporting
of systematic reviews including meta-analyses abstracts is
suboptimal in these top journals, we can extrapolate that
the quality of reporting may be lower in other journals.
Hence, this call for improvement in the quality of reporting
standards could perhaps be generalized.
Conclusions
The reporting quality of abstracts of systematic reviews in-
cluding meta-analyses of RCTs in leading general medicine
journals did not improve in 2014 after the publication of
the PRISMA-A guidelines and only improved slightly in
2015. There is still room for improvement to meet the stan-
dards of the PRISMA-A guidelines. Better structuring of
abstracts and stricter adherence to the PRISMA-A by
authors, reviewers, and journal editors is highly warranted.
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Table 6 Factors associated with a better reporting of items of PRISMA for abstracts published in 2015
Overall reporting quality Methodological reporting quality Results reporting quality
Adjusted incidence rate ratios
(95 % confidence interval)a
p Adjusted incidence rate ratios
(95 % confidence interval)a
p Adjusted incidence rate ratios




≥300 0.80 (0.74; 0.87) <0.001 0.86 (0.59; 0.79) <0.001 1.03 (0.87; 1.22) 0.731
Abstract format
IMRAD (ref) 1
8-headings 1.06 (0.96; 1.17) 0.279 1.33 (1.08; 1.65) .008 1.04 (0.87; 1.24) 0.701
Publication on behalf of a
group
No (ref)
Yes 0.90 (0.80; 1.00) 0.055 0.73 (0.55; 0.96) .027 0.85 (0.64; 1.13) 0.271
Number of authors
≤6 (ref) 1
>6 1.04 (0.97; 1.12) 0.251 1.03 (0.89; 1.19) .721 1.02 (0.88; 1.18) 0.790
Ref reference for mean difference calculation, PRISMA preferred reporting items for systematic review and meta-analysis, IMRAD introduction, methods, results, and discussion
aGeneralized estimation equations with journal as grouping variable. PRISMA endorser variable was excluded from model because it was redundant
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